Concord Health Partners names former Novartis U.S. leader Shaw to advisory board

Concord Health Partners announced Friday it has named Christi Shaw to its advisory board.

The Summit-based health care investment firm said Shaw most recently was named CEO of Kite, a Gilead company. There, she will oversee the development and commercialization of cell therapies with the goal of curing cancer.

“Having seen such remarkable advances in health care over the last few decades while also personally and professionally navigating our U.S. health care system, I’m excited to play a part in advancing and ensuring access to important, life-saving therapies that have the potential to change the way cancer is treated,” Shaw said.

Most recently, Shaw served as senior vice president of Eli Lilly & Co. and president of Lilly Bio-Medicines. Before that, she served as U.S. country head and president of Novartis Corp. and North American head of Novartis Oncology.

She is also a member of several boards, including Avantor Inc. and the Biotechnology Industry Organization. She also serves as an advisor to the Healthcare Businesswomen’s Association.

“We congratulate Christi on her appointment as CEO of Kite and we’re delighted to welcome her to Concord’s Advisory Board. Christi has been a tremendous advocate for patients throughout her distinguished career, always striving to find innovative ways to better serve patients and improve the quality of care. Her thought leadership and extensive strategic, financial and operational experience make her an ideal fit for Concord’s advisory board,” James Olsen, founder and managing partner at Concord, said.